Ibarra-Estrada M et al., 2023-03-13: Single-centre randomised placebo-controlled trial of early methylene blue in septic shock that reports its exact dosing schedule and a shorter time to vasopressor discontinuation. It is one of the few prospective human trials giving a fully specified non-approved regimen.
Patients assigned to MB group received an intravenous (IV) infusion of 100 mg of MB in 500 ml of 0.9% sodium chloride solution over 6 h once daily for a total of 3 doses.
Ibarra-Estrada M et al., 2023-03-13: Single-centre randomised placebo-controlled trial of early methylene blue in septic shock that reports its exact dosing schedule and a shorter time to vasopressor discontinuation. It is one of the few prospective human trials giving a fully specified non-approved regimen. Study type: single-centre RCT, blinded, placebo-controlled, Mexico. N=91 (45 MB, 46 placebo). Dose: 100 mg MB in 500 mL 0.9% NaCl IV over 6 h once daily x 3 doses; authors report the daily weight-based dose delivered was 1.2 mg/kg (IQR 1.1-1.4) and cumulative 3.6 mg/kg over 54 h. Route: intravenous. Duration: 3 days, 28-day follow-up. Comparator: placebo (same volume). Result: time to vasopressor discontinuation 69 h vs 94 h (p<0.001); mortality similar; 'no serious adverse effects related to MB administration'. COI: 'The authors have no competing interests to disclose.' Funder: not stated in the abstract; see paper acknowledgements. Product: 100 mg vials available at the institution (brand not named in text). Study type: randomized trial.
